



CODEN [USA]: IAJPBB

ISSN: 2349-7750

## INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.1292940>

**Available online at:** <http://www.iajps.com>

**Research Article**

### ANALYSIS OF BLOOD PRESSURE MEASUREMENT AND TREATMENT OF HYPERTENSION IN PAKISTANI HOSPITALS

<sup>1</sup>Dr. Jamil Ahmed, <sup>2</sup>Dr. Aneeqa Saleem, <sup>3</sup>Dr. Asad Ullah

<sup>1</sup>Medical Officer at THQ Hospital, Kot Chutta, Dera Ghazi Khan

<sup>2</sup>Nishtar Hospital, Multan

<sup>3</sup>Sheikh Zayed Hospital, Rahim Yar Khan

**Abstract:**

**Introduction:** Hypertension is a consistent, powerful and independent risk factor for cardiovascular disease, stroke and renal disease. Diagnosis of hypertension is based on measurement of blood pressure (BP). Obtaining accurate BP readings has been noted to be a challenge faced by health professionals at all levels. **Aims of the study:** The basic aim of the study is to find the treatments of hypertension and high blood pressure in local hospitals of Pakistan. **Material and method:** This study was done at Nishtar hospital Multan, targeting outpatients. The study population comprised adult (> 18 years) patients, with or without hypertension, who accessed primary care at the hospital during the study period June 2016 to December 2017 and who gave consent to participate in the study. **Results:** Demographic values and treatment of hypertension has direct relationship. As there are many factors which are responsible for medication and treatment in a country like Pakistan. Table 01 explains the demographic values of all male and female patients. **Conclusion:** It is concluded that there is a difference between standard BP treatments which affect the decision to start medication and the decision to initiate treatment, but not the decision regarding alteration of regime for those already on treatment.

**Corresponding author:**

**Dr. Jamil Ahmed,**

*Medical Officer at THQ Hospital,*

*Kot Chutta,*

*Dera Ghazi Khan*

QR code



Please cite this article in press Jamil Ahmed et al., Analysis of Blood Pressure Measurement and Treatment of Hypertension in Pakistani Hospitals, Indo Am. J. P. Sci, 2018; 05(06).

## INTRODUCTION:

Hypertension is a consistent, powerful and independent risk factor for cardiovascular disease, stroke and renal disease [1]. Diagnosis of hypertension is based on measurement of blood pressure (BP). Obtaining accurate BP readings has been noted to be a challenge faced by health professionals at all levels [2]. A large number of surveys have shown that physicians, along with other healthcare providers, seldom follow established guidelines for measurement of BP [3]. This study analysed variations between pragmatic and standardized (as per protocol) BP measurement. Technology has brought in various BP measuring devices, a common one in primary care being the wrist sphygmomanometer as opposed to the 'gold standard', but environmentally unfriendly, mercury sphygmomanometer.

Hypertension is a common health burden affecting both developed and developing nations.<sup>4</sup> The prevalence of high BP increases dramatically with age, with the lifetime risk of high BP approaching 100%.<sup>5</sup> Extensive data have shown beyond doubt the benefit of controlling hypertension [6].

Control of BP begins with accurate measurement that leads to appropriate diagnosis, assessment of cardiovascular risk and treatment decisions. The target BP for patients using anti-hypertensive treatment has been lowered for those with diabetes or renal disease, thus, it has become increasingly important to be able to detect small differences in BP. Whilst BP measurement is a vital clinical skill, it is performed poorly by all categories of healthcare professional [4]. There are, in general, three sources of error in the indirect measurement of BP: (1) observer bias; (2) faulty equipment; and (3) failure on the part of clinicians to standardize the measurement techniques [7].

The mercury sphygmomanometer, because of its accuracy and reliability, is widely regarded as being the gold standard against which all other devices for BP measurement should be compared.<sup>5</sup> As a result of environmental awareness, there has been increasing pressure to remove medical devices containing mercury from clinical areas, which is leading to the gradual decline in use of the mercury sphygmomanometer and, as a result, automated BP devices have been adopted by clinicians for their convenience and ease of use [8].

High blood pressure was the leading risk factor for the overall global burden of disease in 2010. The recent decrease in cardiovascular mortality in high-income countries has been associated with a rise in

the numbers of patients living with cardiovascular disease, and the wider use of preventive drugs [9].

The National Health Survey of Pakistan estimated that hypertension affects 18% of adults and 33% of adults above 45 years old. In another report, it was shown that 18% of people in Pakistan suffer from hypertension with every third person over the age of 40 becoming increasingly vulnerable to a wide range of diseases [10]. It was also mentioned that only 50% of the people with hypertension were diagnosed and that only half of those diagnosed were ever treated. Thus, only 12.5% of hypertension cases were adequately controlled [15]. Some remote areas like Balochistan, there is a paucity of data but the control rate is likely to get even worse.

## Aims of the study

The basic aim of the study is to find the treatments of hypertension and high blood pressure in local hospitals of Pakistan.

## MATERIAL AND METHODS

This study was done at Nishtar hospital Multan, targeting outpatients. The study population comprised adult (> 18 years) patients, with or without hypertension, who accessed primary care at the hospital during the study period June 2016 to December 2017 and who gave consent to participate in the study.

## Sample size and sampling method

Every fourth patient who had attended the outpatient clinic was eligible for selection. A sample size of 60 was used, based on statistical calculations and sample size from similar studies. Informed consent was obtained from eligible patients. Participants had BP assessed in a pragmatic way by nurse practitioners who would give their therapeutic decision based on their readings. Participants had BP re-assessed according to the standard protocol, using mercury sphygmomanometer and wrist sphygmomanometer alternately. To reduce bias, the order of measurement for pragmatic or standard BP measurements was alternated for successive patients. Finally, demographic and relevant clinical data were collected into a 'Data Collection' form, which was subsequently entered into a Microsoft® Excel spreadsheet for analysis.

## Statistical analysis

Microsoft® Excel was used to capture the data and the data analysis software system, STATISTICA

version 9 (StatSoft Inc., 2009), was used to analyze the data.

## RESULTS:

**Table 01:** Demographic characteristics of participants.

| Characteristics                              | Variables | S.D. |
|--|-----------|------|
| Males  | 32        | -    |
| Females                                      | 28        | -    |
| Mean age in years (standard deviation)       | 43        | 14.2 |
| Mean body mass index                         | 29        | -    |
| Prevalence of hypertension                   | 25%       | -    |
| Mid-upper arm circumference (in centimetres) | 32        | -    |

Table 02 explains the treatment decision according to the history of a patients. It is based on the pragmatic blood pressure and standard blood pressure.

**Table 02:** Clinical characteristics of participants.

| Treatment decision                | No treatment |    | Treat |    | Change treatment |    |
|-----------------------------------|--------------|----|-------|----|------------------|----|
|                                   | n            | %  | n     | %  | n                | %  |
| Based on pragmatic blood pressure | 32           | 53 | 18    | 30 | 10               | 17 |
| Based on standard blood pressure  | 41           | 68 | 11    | 18 | 8                | 13 |

Table 03 clearly explains the medication which is used in local hospitals of Pakistan for the treatment of hypertension and high blood pressure

**Table 03:** medication that used for high blood pressure

| Medication                       | Dosage                     | Analysis  |
|----------------------------------|----------------------------|---|
| Telmisartan                      | 40 mg once per day         | Consider alternative in patients with acute kidney injury or severe renal disease; may cause hyperkalemia |
| Atenolol                         | 25 to 50 mg once per day   | Avoid in patients with bradycardia; may cause bronchospasm  |
| Metoprolol succinate (Toprol XL) | 25 to 100 mg once per day  |   |
| Amlodipine (Norvasc)             | 2.5 to 5 mg once per day   | May cause flushing and edema  |
| Nifedipine*                      | 30 mg once per day         |   |
| Hydrochlorothiazide              | 12.5 to 25 mg once per day | Use with caution in patients with gout; may cause hypokalemia and hyponatremia                            |

**DISCUSSION:**

Comparison of wrist and mercury BP measurements was subsequently performed. Standard mercury diastolic and systolic BPs were consistently higher when using a wrist device. For systolic BP, the difference was as much as 20 mmHg, whilst it was approximately 10 mmHg for diastolic BP, a sharp contrast to previous studies which found similarities between mercury and wrist devices.<sup>3</sup> We suspected that the difference was mostly because of the precise arm position and a known problematic phenomenon of wrist devices in which there is a systematic error introduced by the hydrostatic effect of differences in the position of the wrist relative to the heart.<sup>11</sup> This can be avoided if the wrist is always at heart level when the readings are taken, but there is no way of knowing retrospectively whether this was performed when a series of readings are reviewed.<sup>12</sup>

The mercury sphygmomanometer is generally regarded as the gold standard against which all other devices for BP measurement should be compared.<sup>5</sup> However, recent studies have shown that ambulatory BP measurements correlate better with the exact BP. Hodgkinson et al. have recently concluded that ambulatory BP was more cost effective than clinic or home BP. However, guidelines for diagnosis and treatment of hypertension are still based on clinic BP measurements.

Blood pressure elevations during hospitalization are often exacerbated by pain, anxiety, or acute illness. When these factors have been excluded and the patient remains hypertensive, it is best practice to reinitiate or adjust oral antihypertensive therapy in those with preexisting hypertension<sup>8</sup>. Our approach to understand disease development in early life,<sup>13</sup> identify key pathways of interest in predisposition to hypertension and develop specific preventive approaches has been to use multi-modality imaging to capture information on cardiovascular structure and function ‘from heart to capillary’<sup>9</sup>. With this approach it becomes possible to model the interrelationship between features of the cardiovascular system and, with longitudinal data, study the progression of disease across vessel and heart. By extending the data collection to other organs such as brain and liver, a holistic view of disease development can be captured<sup>10</sup>.

High blood pressure was the leading risk factor for the overall global burden of disease in 2010. The recent decrease in cardiovascular mortality in high-income countries has been associated with a rise in the numbers of patients living with cardiovascular disease, and the wider use of preventive drugs.<sup>14</sup>

Thus, an up-to-date understanding of the associations of blood pressure with different non-fatal and fatal cardiovascular disease outcomes would help to refine strategies for primary prevention and inform the design of future clinical trials [15].

**CONCLUSION:**

It is concluded that there is a difference between standard BP treatments which affect the decision to start medication and the decision to initiate treatment, but not the decision regarding alteration of regime for those already on treatment. There are also marked differences between wrist- and standard BP devices which also affect treatment decision-making.

**REFERENCES:**

1. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med*. 1992;152(1):56–64.
2. Petrie JC, O'Brien ET, Littler WA, et al. Recommendations on blood pressure measurement. *Br Med J*. 1986;293:611
3. McKay DW, Campbell NR, Parab LS, et al. Clinical assessment of blood pressure. *J Hum Hypertens*. 1990;4(6):639–645.
4. Abdulkhalek S, Szewczuk MR. Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses. *Cellular Signalling*. 2013;25(11):2093–2105
5. Pshezhetsky AV, Ashmarina LI. Desialylation of surface receptors as a new dimension in cell signalling. *Biochemistry (Mosc)* 2013;78(7):736–745
6. Wang FL, Cui SX, Sun LP, et al: High expression of α2,3-sialic acid residues is associated with the metastatic potential of human gastric cancer. *Cancer Detect Prev* 32: 437-443, 2009
7. Ohyama C, Hosono M, Nitta K, et al: Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. *Glycobiology* 14: 671-679, 2004.
8. Hynes RO: Integrins: bidirectional, allosteric signaling machines. *Cell* 110: 673-687, 2002
9. Taniguchi A, Hioki M and Matsumoto K: Transcriptional regulation of human ST4GalIV gene in testis and ovary cell line. *Biochem Biophys Res Commun* 301: 764-768, 2003.

10. Christie DR, Shaikh FM, Lucas JA IV, Lucas JA III and Bellis SL: ST6Gal-I expression in ovarian cancer cell promotes an invasive phenotype by altering integrin glycosylation and function. *J Ovarian Res* 1: 3-10, 2008.
11. Pierga JY, Deneux L, Bonneton C, Vincent-Salomon A, Nos C, Anract P, Magdelenat H, Pouillart P, Thiery JP: Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients. *Int J Biol Markers*. 2004, 19: 23-31.\
12. Ohyama C, Hosono M, Nitta K, et al: Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. *Glycobiology* 14: 671-679, 2004.
13. Hynes RO: Integrins: bidirectional, allosteric signaling machines. *Cell* 110: 673-687, 2002
14. Taniguchi A, Hioki M and Matsumoto K: Transcriptional regulation of human ST4GalIV gene in testis and ovary cell line. *Biochem Biophys Res Commun* 301: 764-768, 2003.
15. Sala C, Santin E, Rescalдani M, et al. How long shall the patient rest before clinic blood pressure measurement? *Am J Hypertens*. 2009;19(7):713–717.